Ruoyu Zhang, Yunfei Tan, Dedi Jiang, Dewei Kong, Mei Liu, Jianwei Liang, Aiwen Wu, Liming Wang
{"title":"Anoikis and NETosis in colorectal cancer liver metastasis: the relationship and perspectives.","authors":"Ruoyu Zhang, Yunfei Tan, Dedi Jiang, Dewei Kong, Mei Liu, Jianwei Liang, Aiwen Wu, Liming Wang","doi":"10.1016/j.bbcan.2025.189401","DOIUrl":"10.1016/j.bbcan.2025.189401","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a leading cause of cancer-related mortality, with metastatic spread being the primary reason for fatalities. Anoikis, a form of programmed cell death triggered by cell detachment from the extracellular matrix (ECM), and NETosis, a neutrophil cell death mode releasing extracellular traps (NETs), play critical roles in CRC liver metastasis (CRCLM). This review explores the mechanisms of anoikis and NETosis, their interplay, and genetic underpinnings in CRCLM. Anoikis resistance in CRC cells allows survival during metastasis in the initial stage, while NETs promote tumor progression by facilitating immune evasion, ECM remodeling, and angiogenesis. Meanwhile, through bioinformatics analysis and summary, we elaborated on the relationship between anoikis and NETosis as well as the potential interaction mechanisms, exploring the connecting links between them. The crosstalk between these processes is analyzed, highlighting shared signaling pathways (e.g., PI3K/AKT, MAPK, EMT) and potential biomarkers (e.g., MUC13, GLI2, SIRT6, FASN). Therapeutic strategies targeting anoikis and NETosis, including inhibitors of integrins, EGFR, and NET components (e.g., DNase I, CXCR2 antagonists), inhibitors of autophagy (e.g., CQ, HCQ, azithromycin) are discussed. This comprehensive analysis advances understanding of CRCLM pathogenesis and provides novel perspectives for targeted interventions.</p>","PeriodicalId":93897,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":" ","pages":"189401"},"PeriodicalIF":8.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144762666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bashar A Alhasan, Alexey V Morozov, Irina V Guzhova, Boris A Margulis
{"title":"The ubiquitin-proteasome system in the regulation of tumor dormancy and recurrence.","authors":"Bashar A Alhasan, Alexey V Morozov, Irina V Guzhova, Boris A Margulis","doi":"10.1016/j.bbcan.2024.189119","DOIUrl":"10.1016/j.bbcan.2024.189119","url":null,"abstract":"<p><p>Tumor recurrence is a mechanism triggered in sparse populations of cancer cells that usually remain in a quiescent state after strict stress and/or therapeutic factors, which is affected by a variety of autocrine and microenvironmental cues. Despite thorough investigations, the biology of dormant and/or cancer stem cells is still not fully elucidated, as for the mechanisms of their reawakening, while only the major molecular patterns driving the relapse process have been identified to date. These molecular patterns profoundly interfere with the elements of cellular proteostasis systems that support the efficiency of the recurrence process. As a major proteostasis machinery, we review the role of the ubiquitin-proteasome system (UPS) in tumor cell dormancy and reawakening, devoting particular attention to the functions of its components, E3 ligases, deubiquitinating enzymes and proteasomes in cancer recurrence. We demonstrate how UPS components functionally or mechanistically interact with the pivotal proteins implicated in the recurrence program and reveal that modulators of the UPS hold promise to become an efficient adjuvant therapy for eradicating refractory tumor cells to impede tumor relapse.</p>","PeriodicalId":93897,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":" ","pages":"189119"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140960830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Soumyadeep Chattopadhyay, Rudradeep Hazra, Arijit Mallick, Sakuntala Gayen, Souvik Roy
{"title":"A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment.","authors":"Soumyadeep Chattopadhyay, Rudradeep Hazra, Arijit Mallick, Sakuntala Gayen, Souvik Roy","doi":"10.1016/j.bbcan.2024.189110","DOIUrl":"10.1016/j.bbcan.2024.189110","url":null,"abstract":"<p><p>Oncolytic viruses (OVs) are increasingly recognized as potent tools in cancer therapy, effectively targeting and eradicating oncogenic conditions while sparing healthy cells. They enhance antitumor immunity by triggering various immune responses throughout the cancer cycle. Genetically engineered OVs swiftly destroy cancerous tissues and activate the immune system by releasing soluble antigens like danger signals and interferons. Their ability to stimulate both innate and adaptive immunity makes them particularly attractive in cancer immunotherapy. Recent advancements involve combining OVs with other immune therapies, yielding promising results. Transgenic OVs, designed to enhance immunostimulation and specifically target cancer cells, further improve immune responses. This review highlights the intrinsic mechanisms of OVs and underscores their synergistic potential with other immunotherapies. It also proposes strategies for optimizing armed OVs to bolster immunity against tumors.</p>","PeriodicalId":93897,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":"1879 4","pages":"189110"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140960831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}